©The Author(s) 2025.
World J Clin Oncol. Sep 24, 2025; 16(9): 109034
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109034
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109034
Table 5 Prophylactic use of hyperthermic intraperitoneal chemotherapy, randomized controlled trials: Study and population characteristics, treatments and outcomes
| Year | Ref. | State | Arms | Patient cohort | HIPEC sample | Oncological admission criteria (TNM stage) | Bedsite HIPEC | HIPEC protocol | Neoadjuvant CHT | Neoadjuvant treatment regimen | Adjuvant Cht | Adjuvant treatment regimen |
| 2014 | Cui et al[36] | China | Arm 1: Surgery alone (n = 48). Arm 2: Neoadjuvant Cht + surgery (n = 48). Arm 3: Surgery + postoperative HIPEC (n = 48). Arm 4: Neoadjuvant Cht + surgery + postoperative HIPEC (n = 48) | 192 | Arm 3 + 4: n = 98 | IIIA-IIIC + no Neoadjuvant Cht before enrollement | Yes | Day 1 and 4: 60 mg/m2 cisplatin, 90 minutes. Day 2 and 3: 0.75 g fluorouracil, 90 minutes +1000 cc of perfusate left in place for 23 hours at the end of each cycle | Yes | Paclitaxel, cisplatin, tegafur | Yes, if tumor progression occurred during neodjuvant treatment | Epirubicin, cisplatin, fluorouracil |
| 2019 | Reutovich et al[37] | Belarus | Arm 1: Gastrectomy + HIPEC (n = 76). Arm 2: Gastrectomy only (n = 78) | 154 | 76 | IIB-IIIC + Borrmann type III-IV | No | Cisplatin 50 mg/m2 + doxorubicin 50 mg/m2, 60 minutes closed abdomen | No | _ | No | Not declared |
| 2021 | Fan et al[38] | China | Arm 1: S.Cht (n = 17). Arm 2: T-HIPEC + adjuvant S.Cht (n = 33) | 50 | 33 | IIIA-B | No | Cisplatin (50 mg/L), 30 minutes | No | _ | Yes | S1 + oxaliplatin |
| 2022 | Liu et al[39] | China | 4 weeks after D2 gastrectomy: Arm 1: Bedside HIPEC + oral S1 treatment; arm 2: IV cisplatin + oral S1 treatment | 114 | 57 | III A-B | Yes | Day 1 and 3: Cisplatin (30 mg/m2) + oral S1, (40-60 mg for 14 days) | No | _ | Yes | 6-8 cycles of IV cisplatin (60 mg/m2) + oral S1 (40-60 mg, 2/day) |
| 2023 | Yu et al[40] | China | Arm 1: HIPEC + Cht. Arm 2: Systemic chemotherapy alone | 134 | 67 | IIIA and B + no Neoadjuvant Cht before enrollement | Yes | Cisplatin (40 mg/m2), 60 minutes, 2 cycles within 72 hours after surgery | No | _ | Yes | 6-8 cycles of S1 + oxaliplatin |
- Citation: D'Acapito F, Framarini M, Morgagni P, Di Pietrantonio D, Vittimberga G, Zucchini V, Ercolani G. Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes. World J Clin Oncol 2025; 16(9): 109034
- URL: https://www.wjgnet.com/2218-4333/full/v16/i9/109034.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i9.109034